Pelacarsen Phase 3 Miss Removes Key Non-Oncology Upside; Novartis Premium Multiple Faces De-Risking

What happened

The pelacarsen Lp(a)HORIZON outcomes trial failed to meet its primary composite endpoint, eliminating the largest non-oncology catalyst in Novartis' H2 2026 slate. The miss occurred despite pelacarsen's known substantial Lp(a) lowering, underscoring that biomarker reduction did not translate into cardiovascular event reduction in this population. This removes a key source of premium valuation support at a time when the stock already trades at 23.1x earnings with H1 sales down 2% in constant currency. The remaining H2 catalysts—remibrutinib in MS and del-desiran in myotonic dystrophy—now carry heavier weight, and Pluvicto's mHSPC approval becomes the primary near-term offset. Absent a positive surprise elsewhere, the bear scenario at $128 gains probability and the base implied value of $158 should be trimmed.

Implication

The failure of pelacarsen to reduce cardiovascular events reduces the probability-weighted value of the bull case and pushes the base scenario toward the lower end of the prior range. The stock's 23.1x P/E is now harder to justify without a clear late-stage win, leaving the valuation more dependent on Pluvicto label expansion and commercial execution against Entresto erosion. We lower our base implied value from $158 to approximately $150 and raise the bear scenario probability from 30% to 40%, making the $140 entry more attractive but not yet a mandatory buy. If remibrutinib or del-desiran also fails, the bear scenario at $128 becomes the central case and existing positions should be reduced. Conversely, a successful Pluvicto approval plus one other catalyst could stabilize the stock near $150–155, but the margin of safety at $152 is inadequate.

Thesis delta

The investment thesis previously relied on at least one major H2 2026 readout succeeding to justify the premium multiple; pelacarsen's miss removes the largest such catalyst. We now assign lower probability (near 15% from 25%) to the bull case and higher probability (near 40% from 30%) to the bear case, trimming our base implied value to about $150. The WAIT rating is reinforced, with a more disciplined entry near $140 and a re-assessment window of 3-6 months for Q3 results and remaining catalysts.